Kyle Crassini - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

All papers authored by Kyle Crassini

This paper was not found in any repository, but could be made available legally by the author.

2021 Narjis Fatima, Yandong Shen

ORCID

, Kyle Crassini

ORCID

, Edwin J. Iwanowicz, Henk Lang, Donald S. Karanewsky, Richard I. Christopherson, Stephen P. Mulligan, Oliver G. Best

ORCID

The ClpP activator ONC‐212 (TR‐31) inhibits BCL2 and B‐cell receptor signaling in CLL

Upload

This paper is made freely available by the publisher.

2020 Yandong Shen

ORCID

, Kyle Crassini

ORCID

, Narjis Fatima

ORCID

, Michael O’Dwyer, Michael O’Neill

ORCID

, Richard I. Christopherson, Stephen P. Mulligan, O. Giles Best

ORCID

IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment

Download from doi.org

This paper was not found in any repository, but could be made available legally by the author.

2018 Kyle Crassini

ORCID

ORCID

, Michael O'Dwyer, Michael O'Neill, Richard Christopherson, Stephen Mulligan, O. Giles Best

ORCID

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment

Upload

This paper is made freely available by the publisher.

Kyle Crassini

ORCID

ORCID

, William S. Stevenson, Richard Christopherson, Chris Ward, Stephen P. Mulligan, O. Giles Best

ORCID

MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment

Download from api.wiley.com

Missing publications? Search for publications with a matching author name.